Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of "Buy" from Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has received an average recommendation of "Buy" from the seventeen analysts that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $40.63.

DYN has been the subject of several recent research reports. Evercore ISI restated an "outperform" rating on shares of Dyne Therapeutics in a research note on Friday, July 11th. Oppenheimer initiated coverage on Dyne Therapeutics in a report on Monday, June 2nd. They issued an "outperform" rating and a $34.00 price objective for the company. Raymond James Financial initiated coverage on Dyne Therapeutics in a report on Wednesday, June 11th. They issued an "outperform" rating and a $37.00 price objective for the company. Chardan Capital reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, June 17th. Finally, Robert W. Baird dropped their price objective on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a report on Wednesday, June 18th.

Insider Transactions at Dyne Therapeutics

In related news, CEO John Cox purchased 100,000 shares of Dyne Therapeutics stock in a transaction on Monday, July 14th. The shares were purchased at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the transaction, the chief executive officer owned 242,179 shares of the company's stock, valued at approximately $2,206,250.69. This represents a 70.33% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 14.14% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. grew its position in shares of Dyne Therapeutics by 52.2% in the 1st quarter. RA Capital Management L.P. now owns 9,714,392 shares of the company's stock valued at $101,613,000 after buying an additional 3,333,248 shares during the last quarter. Atlas Venture Life Science Advisors LLC grew its position in shares of Dyne Therapeutics by 13.9% in the 1st quarter. Atlas Venture Life Science Advisors LLC now owns 9,130,465 shares of the company's stock valued at $95,505,000 after buying an additional 1,111,111 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Dyne Therapeutics by 10.5% in the 1st quarter. Vanguard Group Inc. now owns 7,406,344 shares of the company's stock valued at $77,470,000 after buying an additional 702,418 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Dyne Therapeutics by 8.3% during the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company's stock valued at $173,808,000 after purchasing an additional 566,146 shares in the last quarter. Finally, Braidwell LP boosted its position in shares of Dyne Therapeutics by 431.6% during the 1st quarter. Braidwell LP now owns 3,621,344 shares of the company's stock valued at $37,879,000 after purchasing an additional 2,940,162 shares in the last quarter. Institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Trading Up 0.8%

Shares of NASDAQ DYN opened at $9.40 on Friday. Dyne Therapeutics has a 12 month low of $6.36 and a 12 month high of $47.45. The stock has a 50 day moving average of $11.24 and a 200-day moving average of $12.40. The company has a market capitalization of $1.07 billion, a P/E ratio of -2.62 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). Analysts predict that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.